NMN for Sleep & Insomnia: What the Evidence Shows
NMN sleep evidence is small and mixed. The timing trial used evening doses without establishing a sleep-quality advantage; another trial found a modest signal.
Updated
3 min read · 10 sources
On this page
NMN is marketed for sleep and recovery, but the human evidence supports a narrower conclusion: a few small studies suggest sleep-related benefits, while others do not. The most-cited timing trial also needs careful reading. Its later-dose group took NMN after 6 p.m. until bedtime, and improvements in that group did not establish an overall sleep-quality advantage over placebo 1. It does not justify a rule to take NMN at lunchtime, in the morning, or at bedtime.
What the main randomized studies found
Featured partner
CoreAge Rx
From $93/mo
Check availabilityRead our reviewAffiliate link. We may earn a commission at no extra cost to you.
Affiliate partner
MadeMed
NAD+ injection & nasal spray, in 23 states
See MadeMedTwo frequently cited trials tested 250 mg/day for 12 weeks in older Japanese adults, but they did not reach identical conclusions.
Kim and colleagues randomized 108 participants across morning NMN, evening NMN, morning placebo and evening placebo. The later NMN group had the largest within-group effect sizes for drowsiness and sit-to-stand performance. However, drowsiness also improved in the evening placebo group, and all four groups improved on sit-to-stand. The group-by-time test for overall sleep quality was not significant 1. Those comparisons matter more than selecting the group with the largest change and declaring it the winner.
12-week NMN sleep trial
Baseline
Four randomized groups
108 adults; NMN or placebo at each time window.
Weeks 1–12
250 mg/day or placebo
Waking to noon, or 6 p.m. to bedtime.
Assessment
Mixed findings
No significant overall sleep-quality interaction; placebo effects also present.
Morifuji and colleagues studied 60 older adults. Their trial reported lower global Pittsburgh Sleep Quality Index (PSQI) and daytime-dysfunction scores with NMN versus placebo at 12 weeks 2. That is a positive signal, but the participants were not selected for chronic insomnia and the study focused on NAD+ and physical function. It does not establish that NMN treats a sleep disorder.
The evidence is not uniformly positive: an eight-week, uncontrolled study in 11 middle-aged men raised NAD+ without improving sleep-quality scores 9. Its design cannot settle efficacy either way, but higher NAD+ should not be presented as a guarantee of better sleep.
What the timing trial actually tested
The morning window ran from waking until noon; the later window ran from 6 p.m. until bedtime 1. Although the paper calls its PM condition “afternoon,” that wording should not be turned into lunchtime advice. Nor did the study isolate a fixed dose immediately before sleep.
Strength of evidence by claim
- Subjective sleep quality in older adultsWeak evidence
Small trials with mixed findings; daytime function is part of the score.
- Evening NMN timingWeak evidence
One timing trial; placebo improved too and overall sleep interaction was not significant.
- Established treatment for chronic insomniaNone evidence
Not demonstrated by these older-adult studies; a trial protocol is not a result.
- An optimal hour or dose for sleepNone evidence
No validated bedtime, lunchtime or dose recommendation.
Circadian biology explains why researchers ask this question. Laboratory work links CLOCK–SIRT1, NAMPT and daily NAD+ rhythms 45; our circadian-rhythm guide explains the proposed connection. Single-dose human work also shows changes in downstream nicotinamide metabolites after NMN 3. Neither establishes the best hour to take a supplement for sleep. A mechanism cannot resolve a timing comparison that did not show clear sleep-quality superiority.
The best-time-to-take-NMN guide covers routines and food separately. The conclusion for sleep is that an optimal schedule has not been established.
Sleep-quality scores are not the same as treating insomnia
PSQI combines several aspects of sleep and daytime functioning. A better score can be useful, but it does not automatically mean faster sleep onset, objectively longer sleep, or remission of chronic insomnia. The larger of the two older-adult trials excluded people receiving treatment for sleep disorders 1.
A separate 2023 protocol proposed a 400-person trial of 320 mg/day NMN for 60 days in chronic insomnia 10. A protocol describes intended methods; it is not a positive result. The completed studies discussed here do not establish NMN as an insomnia treatment, and small preliminary reports require independent replication before supporting routine care.
Persistent insomnia deserves assessment for sleep apnea, medication effects and other causes, with established insomnia treatment discussed with a clinician. It should not be managed by escalating NMN on the assumption that more NAD+ means more sleep.
What a higher NAD+ result can tell you
Controlled studies show that oral NMN can increase blood NAD+ 67. Animal work also reports age-related physiological effects 8. These findings establish biological activity, not a reliable sleep benefit or a dose for treating insomnia. The 250 mg/day used in the two older-adult studies is a research regimen; higher doses have not been established as better for sleep.
For the broader decision, see our dosage guide, the evidence for energy benefits, and why some people stop taking NMN. The same older-adult findings are sometimes recast as a menopause treatment; our menopause review explains why that transfer is unsupported. Our NAD+ evidence guide and product comparison put these uncertain sleep findings in context.
Frequently asked questions
Does NMN actually help you sleep?
Small studies give mixed results. One older-adult trial reported improved subjective sleep-quality scores, while the larger timing trial did not show a significant overall sleep-quality interaction. These findings do not establish NMN as a treatment for insomnia.
Should I take NMN at night for better sleep?
No optimal time has been established. The timing trial did include an evening window, from 6 p.m. until bedtime, but placebo participants also improved and overall sleep-quality differences were not significant. It does not justify a bedtime or lunchtime recommendation.
Can NMN treat insomnia?
It is not an established insomnia treatment. The older-adult studies discussed here do not demonstrate treatment of chronic insomnia. A published protocol planned a dedicated 400-person insomnia trial, but a protocol is not evidence of benefit.
How much NMN did the sleep trials use?
The two main older-adult randomized studies used 250 mg/day for 12 weeks. That describes what researchers tested, not a proven insomnia dose. Higher doses have not been established as better for sleep.
References
- Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T (2022). Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. https://pubmed.ncbi.nlm.nih.gov/35215405/
- Morifuji M, Higashi S, Ebihara S, Nagata M (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. https://pubmed.ncbi.nlm.nih.gov/38789831/
- Irie J, Inagaki E, Fujita M, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal. https://pubmed.ncbi.nlm.nih.gov/31685720/
- Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P (2009). Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. https://pubmed.ncbi.nlm.nih.gov/19286518/
- Ramsey KM, Yoshino J, Brace CS, et al. (2009). Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. https://pubmed.ncbi.nlm.nih.gov/19299583/
- Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
- Okabe K, Yaku K, Uchida Y, et al. (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in Nutrition. https://pubmed.ncbi.nlm.nih.gov/35479740/
- Mills KF, Yoshida S, Stein LR, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/28068222/
- Yamaguchi S, Irie J, Mitsuishi M, et al. (2024). Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men. Endocrine Journal. https://pubmed.ncbi.nlm.nih.gov/38191197/
- Gao X, Li J, Xu S, et al. (2023). Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial. Trials. https://pubmed.ncbi.nlm.nih.gov/37202819/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related reading
NMN for Menopause & Perimenopause: What the Evidence Shows
NMN has a metabolic trial in postmenopausal women, but it does not establish symptom relief. Sleep studies also do not prove a menopause benefit.
ReadNMN for Athletes: Does It Improve Endurance and VO₂ Max?
NMN changed threshold measures in one runners trial without a VO₂ max benefit. A 2026 muscle-biopsy trial adds caution about recovery claims.
ReadNMN for Fertility and Egg Quality: What the Evidence Shows
NMN fertility research includes human egg-culture studies. Review the findings and why oral treatment and live-birth benefits remain unproven.
ReadNAD+ for Long COVID and ME/CFS: What the Evidence Shows
A 58-person NR trial raised NAD+ without improving long COVID symptoms over placebo. Compare that result with the NAD+ patch pilot and ME/CFS studies.
ReadBest Time to Take NMN: Morning, Night, or With Food?
No optimal time to take NMN is established. A trial compared morning with evening, but placebo improvements limit claims of a sleep benefit.
ReadNAD+ for Hearing Loss & Tinnitus: What the Evidence Shows
A small hospital trial of intramuscular NAD+ reported better sudden-hearing-loss outcomes. Review the 45-patient design, limitations and tinnitus claims.
Read